About

Hedy Kindler, MD, is a Professor of Medicine and Associate Dean of Clinical Science Research at the University of Chicago. Her clinical interests focus on gastrointestinal stromal tumors (GIST) and mesothelioma. Dr. Kindler has contributed extensively to the understanding and management of mesothelioma, including the development of consensus guidelines for its treatment and management. Her research encompasses immune composition and immunotherapy outcomes in mesothelioma, as well as the application of radiomics and convolutional neural networks for diagnosis and segmentation of mesothelioma. She is actively involved in advancing clinical practices and research in thoracic and peritoneal mesothelioma, with a focus on improving patient outcomes through multidisciplinary approaches.

Research topics

• Medicine
• Oncology
• Internal medicine
• Data Mining
• Computer Science
• Biology
• Pathology
• Nanotechnology
• Materials science
• Computational biology
• Surgery
• Radiology
• Cancer research
• Gastroenterology
• Nuclear medicine
• Genetics
• Bioinformatics

Selected publications

• Mesothelioma of the Tunica Vaginalis Testis

  Clinical Genitourinary Cancer · 2025-08-07 · 1 citations

  article
  PublisherDOI

• Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights

  JCO Oncology Practice · 2025-03-07 · 5 citations

  article1st authorCorresponding
  PublisherDOI

• Treatment of Pleural Mesothelioma: ASCO Guideline Update

  Journal of Clinical Oncology · 2025-01-08 · 45 citations

  article1st authorCorresponding

  ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more . PURPOSE To provide evidence-based recommendations to practicing physicians and others on the management of pleural mesothelioma (PM). METHODS ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pathology, cancer genetics, and advocacy experts to conduct an updated literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2016 through 2024. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS The literature search identified 110 additional relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS Evidence-based recommendations were developed for surgical cytoreduction, immunotherapy, chemotherapy, pathology, and germline testing in patients with PM. Additional information is available at www.asco.org/thoracic-cancer-guidelines .

  PublisherDOI

• Consensus guideline for the management of peritoneal mesothelioma

  Cancer · 2025-06-25 · 2 citations

  articleOpen access

  The treatment of peritoneal mesothelioma (PeM) poses significant challenges because of its rare incidence, heterogeneity, and limited clinical evidence. This commentary describes results from a national consensus aimed at addressing the management of PeM. An update of the 2018 Chicago consensus guidelines was conducted with a modified Delphi technique, which encompassed two rounds of voting. The levels of agreement for various pathway blocks were assessed. Of 101 participants responding in the first round of modified Delphi voting, 95 (94%) responded in the second round. Over 90% consensus was achieved in five of six and six of six pathway blocks in rounds 1 and 2, respectively. Observation was recommended for benign neoplasms, with guidance for interventions in the presence of symptoms or concerning clinicopathological features. For malignant pathology, management was outlined on the basis of a multidisciplinary assessment of patient characteristics, disease histology, and predictive success of medical and surgical interventions. Additional emphasis was placed on multimodal therapy for intermediate-risk and appropriate high-risk patients. A rapid review demonstrated the limited availability of data and inconclusive findings regarding optimal systemic therapy timing. There was unanimous support for considering clinical trial enrollment. Given the limited evidence, the consensus-driven pathway provides essential guidance regarding the management of PeM. To further direct clinical care, additional dedicated research to generate higher quality evidence is needed.

  PublisherOA PDFDOI

• Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients

  UNC Libraries · 2025-05-23

  articleOpen access
  PublisherDOI

• Unveiling the mystery: A rare case of hypophosphatemia

  Journal of Onco-Nephrology · 2025-04-10

  article

  Tumor-induced osteomalacia (TIO) or oncogenic osteomalacia is a rare paraneoplastic syndrome characterized by an autonomous and unregulated production of fibroblast growth factor 23 (FGF23), which promotes urinary phosphorus wasting and systemic hypophosphatemia. Clinical manifestations are often nonspecific and unfortunately, the syndrome is underdiagnosed or recognized late. Hypophosphatemia is often attributed to other more common etiologies and is often not identified at all, leading to a more advanced disease at the time of diagnosis. Thus, it is necessary to have a high index of suspicion when evaluating hypophosphatemia, as early identification and intervention of TIO can prevent or reverse osteomalacia and lead to an expedited investigation of a culprit neoplasm. We describe a case of TIO associated with established mesothelioma and outline the diagnostic steps taken that ultimately taken to reach a final diagnosis. While rare, this condition should not be missed by the conventional nephrologist, who routinely measures phosphorus levels in their patients, and thus, we provide a framework to follow in the assessment of hypophosphatemia and the ultimate diagnosis of TIO.

  PublisherDOI

• 1697 Molecular Patterns of Bicavitary Mesothelioma

  Laboratory Investigation · 2025-03-01

  article
  PublisherDOI

• Immune Composition and Immunotherapy Outcomes of Mesothelioma With BAP1, CDKN2A, MTAP, and NF2 Alterations

  Journal of Thoracic Oncology · 2025-06-25 · 7 citations

  articleSenior author
  PublisherDOI

• P3.14.04 High-Volume Surgical Centers for Pleural Mesothelioma Are Associated With Lower Perioperative Mortality

  Journal of Thoracic Oncology · 2025-10-01

  article
  PublisherDOI

• LBA104 Primary results of DREAM3R: DuRvalumab (MEDI4736) with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma: A phase III randomised trial

  Annals of Oncology · 2025-09-01

  article
  PublisherDOI

Recent grants

• UG1 - NCTN (Network Lead)

  NIH · $3.7M · 2019–2026

• NCI National Clinical Trials Network-Network Lead Academic Participating Sites

  NIH · $3.2M · 2014–2019

• NIH Grant U10CA041287

  NIH · $6.7M · 2015

• NIH Grant R21CA140003

  NIH · $378k · 2012

• Community Outreach and Engagement

  NIH · $100.1M · 1997–2029

Frequent coauthors

• Richard M. Goldberg

  Applied Physical Sciences (United States)

  273 shared

• Donna Niedzwiecki

  Duke University

  235 shared

• Federico Innocenti

  University of North Carolina at Chapel Hill

  228 shared

• Kouros Owzar

  Duke University

  226 shared

• Alan P. Venook

  225 shared

• Herbert I. Hurwitz

  Duke University

  213 shared

• Mary F. Mulcahy

  Northwestern Medicine

  205 shared

• Eileen M. O’Reilly

  Memorial Sloan Kettering Cancer Center

  197 shared